Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
12.42
-0.18 (-1.43%)
At close: Jul 31, 2025, 4:00 PM
12.15
-0.27 (-2.17%)
After-hours: Jul 31, 2025, 6:53 PM EDT
Crescent Biopharma Stock Forecast
Stock Price Forecast
The 3 analysts that cover Crescent Biopharma stock have a consensus rating of "Strong Buy" and an average price target of $25.67, which forecasts a 106.68% increase in the stock price over the next year. The lowest target is $22 and the highest is $28.
Price Target: $25.67 (+106.68%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Crescent Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 1 | 2 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Initiates $27 | Buy | Initiates | $27 | +117.39% | Jul 14, 2025 |
| Stifel | Stifel | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +125.44% | Jun 25, 2025 |
| LifeSci Capital | LifeSci Capital | Buy Initiates $22 | Buy | Initiates | $22 | +77.13% | Jun 18, 2025 |
| Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 15, 2021 |
| Raymond James | Raymond James | Buy Maintains $285 → $270 | Buy | Maintains | $285 → $270 | +2,073.91% | Aug 6, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.49
from -13.45
EPS Next Year
-3.58
from -3.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | 23.6M |
| Avg | n/a | n/a | 5.7M |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.10 | -3.15 | -3.15 |
| Avg | -3.49 | -3.58 | -3.30 |
| Low | -4.75 | -3.71 | -3.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.